1643 – Efficacy Of Agomelatine In More Anxious Elderly Depressed Patients. a Randomized, Double-blind Study vs Placebo

@article{Heun20131643E,
  title={1643 – Efficacy Of Agomelatine In More Anxious Elderly Depressed Patients. a Randomized, Double-blind Study vs Placebo},
  author={Reinhard Heun and Ricardo Corral and Antti Ahokas and Humberto Nicolini and Jo{\~a}o Marques Teixeira and P. Dehelean},
  journal={European Psychiatry},
  year={2013},
  volume={28},
  pages={1 - 1}
}
Agomelatine, has been shown to be effective and well-tolerated, in treating: major depressive disorder, anxiety symptoms of depression (1,2) and Generalized Anxiety Disorder (3,4). The present analysis evaluate the antidepressant efficacy of agomelatine in the more anxious elderly depressed patients ≥ 65 years, based on a score of the HAMD combined items 10 and 11 ≥ 5 at baseline. In this 8-week international double-blind randomized study, among 222 elderly depressed out-patients randomized… Expand
4 Citations
Pharmacotherapy for social anxiety disorder (SAnD).
TLDR
The SSRIs were the only medication proving effective in reducing relapse based on moderate-quality evidence, and this systematic review is an update of an earlier review of pharmacotherapy of SAnD. Expand
The emergence of new antidepressants for clinical use: Agomelatine paradox versus other novel agents
TLDR
This review remarkably advocates for the incorporation of the atypical antipsychotics and NMDA-glutamatergic ionoceptor blockers as new member classes of the antidepressant agents because of their clinically significant roles in the management of depression disorders. Expand
Moving from the old monoaminergic theory toward the emerging hypothesis in the rational design of rapid-onset novel antidepressants
TLDR
Clinical data suggest the involvement of the glutamatergic neurotransmission system in the pathophysiology of major depression disorder (MDD) or bipolar depression or schizoaffective depression, which includes disruptions in glutamatorgic substrate concentrations and NMDAR alterations. Expand
Neuropharmacological classification of antidepressant agents based on their mechanisms of action
TLDR
This review remarkably advocates for the incorporation of the atypical antipsychotics and NMDA-glutamatergic ionoceptor antagonist/inverse agonist/partial agonist as new member classes of the antidepressant agents because of their clinically significant roles in the management of depression disorders. Expand